Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Michael W. Weiner to Speak at CNS Diseases World Summit September 13-14 San Francisco - Michael W. Weiner, Professor at UCSF and Director at DVA Medical Center San Francisco will give a featured presentation at the 6th Neurodegenerative Conditions Research and Development conference (September 13-14, San Francisco, CA) - GTCbio.com
Michael W. Weiner to Speak at CNS Diseases World Summit September 13-14 San Francisco

 

PRZOOM - /newswire/ - Monrovia, CA, United States, 2012/07/24 - Michael W. Weiner, Professor at UCSF and Director at DVA Medical Center San Francisco will give a featured presentation at the 6th Neurodegenerative Conditions Research and Development conference (September 13-14, San Francisco, CA) - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Michael W. Weiner, M.D., Professor at UCSF and Director at DVA Medical Center San Francisco will give a featured presentation on “Biomarkers for Clinical Diagnosis, Early Detection and Monitoring the Progression of Alzheimer’s Disease for Clinical Trials: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)” at the 6th Neurodegenerative Conditions Research and Development conference taking place on Sept 13-14, 2012 in San Francisco, CA.

The goal of ADNI (from 2004-2010) is to determine the value of MRI and PET imaging together with blood and CSF biomarkers for disease modifying Alzheimer’s treatment trials. In the initial project, Dr. Weiner longitudinally studied: MCI (n= 400); AD (n= 200); Controls (n= 220) with clinical visits, neuropsychological assessments, MRI (1.5 T), FDG PET blood and urine and CSF. He found that the rate of hippocampal atrophy had high statistical power for measuring change over time. Fata from the normal controls suggests that normal healthy elders with APOE4 and/or low CSF A? amyloid have worse memory scores and higher rates of hippocampal atrophy, consistent with the hypothesis that some controls have preclinical AD pathology. Similar ADNI-like projects, with similar methods, are underway in Australia, Japan, Europe, China, Taiwan, and Korea leading to the “World Wide ADNI network.” ADNI 2 (total funding for all ADNI projects now $140 million) is now underaway with m 3Tesla MRI and F18 amyloid PET imaging with Florbetapir on an additional 150 controls, 300 subjects with early MCI, 150 subjects with late MCI and 150 subjects with dementia due to AD. ADNI methods are now widely used in clinical treatment trials, and have led to the development of the “new” research criteria for AD developed by the Alzheimer’s Association and NIH.

In 1980 Dr. Weiner performed the first experiment using implanted coils to obtain 31P NMR spectra from the kidney of living rats, beginning his work using NMR/MRI for research. Since1980 he has been at the San Francisco VA/UCSF. He is currently Director of the Center for Imaging of Neurodegenerative Diseases. He is Professor of Radiology, Medicine, Psychiatry, and Neurology at UCSF. He has published over 600 peer reviewed scientific papers. His grants include studies of Alzheimer’s disease, vascular dementia, frontotemporal dementia, HIV/AIDS, gulf war illness, posttraumatic stress disorder, traumatic brain injury, amyotrophic lateral sclerosis, epilepsy, and other neurodegenerative conditions. He is the Principal Investigator of: the NIA funded Alzheimer’s Disease Neuroimaging Initiative (ADNI)/Grand Opportunities (GO) Grant, and the renewal of ADNI (total funding over $150 million for these 3 grants). Recently he was awarded a grant from the DOD entitled Effects of traumatic brain injury and post traumatic stress disorder on Alzheimer’s disease (AD) in Veterans using ADNI. In 2006 Dr. Weiner was awarded the Middleton Award, for outstanding research in the VA. In 2010 he was awarded the Gold Medal of Paul Sabatier University in Toulouse France, and the Gold Medal of the city of Toulouse, France. In 2011 he accepted the Ronald and Nancy Reagan Research Award from the Alzheimer’s Association on behalf of ADNI.

GTC’s 6th Neurodegenerative Conditions Research and Development conference brings together leading scientists and experts to discuss the latest breakthroughs, new drug targets, new models, the development of new biomarkers, imaging modalities, and several other novel developments and therapeutics to combat neurodegenerative conditions. The conference is also a part of the 2nd CNS Diseases World Summit, which has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partneriing and deal-making.

Join your colleagues at this exciting Neurodegenerative Conditions conference and CNS Diseases summit, and hear from and meet with key representatives in the field including Charles B. Nemeroff at University of Miami, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Stephen Brannan – VP at Takeda, Barry Brand - Chief Executive Officer at CeNeRx, Michael W. Weiner at UCSF, George Garibaldi - SVP and Global Head of Neuroscience Development at F. Hoffmann-La Roche, Marcelle Bergeron at Elan, Beth J. Hoffman – VP at Targacept, Li Gan at Gladstone Institute, and many more!

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Michael W. Weiner to Speak at CNS Diseases World Summit September 13-14 San Francisco

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-1029
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today